Sollentuna 1:a September 2022

Sensidose reinforces its management. Philip Slätis has been hired as Chief Operating Officer and Deputy CEO of Sensidose AB. Philip will take up the position on 1st November in 2022.

– Philips’ broad experience from all parts of the Nordic pharmaceutical market and international networks will be a great asset in our continued expansion and business development in existing and new areas and I am pleased to welcome him to Sensidose. I look forward to our collaboration to strengthen ourselves in existing markets and develop Sensidose globally as the leading company in individualized refined levodopa for the treatment of Parkinson’s disease,” said Sensidose CEO Jack Spira.

Philip has extensive experience from the pharmaceutical industry and has previously held several positions at Swedish and international pharmaceutical companies. Philip most recently came from a position as Head of Business Development at the pharmaceutical company Unimedic, where he has been responsible for the expansion of the company’s existing products and services and in-licensing of new products since 2020.

– I am very happy and grateful to have the opportunity to start in Sensidose at an incredibly exciting time. The need for more individualized treatment together with Sensidose’s technology and ambitious growth plans is a unique opportunity, says Philip Slätis.

For further information, please contact:

Jack Spira, CEO Sensidose, phone +46 (0)722 50 62 72

Sensidose in brief

Sensidose AB is a Swedish pharmaceutical company that has developed and commercialized an innovative system for dosing tablets, which allows an individualized optimization of the medical treatment of Parkinson’s disease. The company has sales of its proprietary product Flexilev in Scandinavia. Flexilev is given using the myFID dose dispenser, which allows accurate and individual titration at each dose.

For more information about Sensidose AB, please contact: Jack Spira, CEO, +46 (0)722 50 62 72